Intravenous Iron Sucrose versus Oral Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease-A Randomized, Controlled, Open-Label, Multicenter Study

Schröder, Oliver; Mickisch, O; Seidler, Ursula; Weerth, Andreas de; Dignaß, Axel; Herfarth, Hans H; Reinshagen, Max; Schreiber, Stefan; Junge, Ulrich; Schrott, M; Stein, Jürgen M.

doi:10.1111/j.1572-0241.2005.00250.x

Cited by 202 publications

(212 citation statements)

References 26 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…Another therapeutical option is the treatment with iron i.v. [15] , particularly iron sucrose together with erythropoietin; this combination is effective but its clinical use is limited by high cost and difficulty of administration [16] . In this study we proposed an alternative and potential new treatment for iron deficient anemia in inflammatory bowel disease using a new food supplement with high content of fish cartilage that was well tolerated and without major adverse reactions.…”

Section: Discussionmentioning

confidence: 99%

A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study

Belluzzi

Roda²,

Tonon³

et al. 2007

WJG

View full text Add to dashboard Cite

AIM:To investigate the effect of a new oral preparation, highly concentrated in fish cartilage, in a group of inflammatory bowel diseases (IBD) patients with chronic iron deficient anemia. METHODS:In an open label pilot study, we supplemented a group of 25 patients (11 with Crohn's disease and 14 with ulcerative colitis) in stable clinical conditions and chronic anemia with a food supplement which does not contain iron but contains a standardized fraction of fish cartilage glycosaminoglycans and a mixture of antioxidants (Captafer Medestea, Turin, Italy). Patients received 500 mg, twice a day during meals, for at least 4 mo. Patients were suggested to maintain their alimentary habit. At time 0 and after 2 and 4 mo, emocrome, sideremia and ferritin were examined. Paired data were analyzed with Student's t test. RESULTS:Three patients relapsed during the study (2 in the 3 rd mo, 1 in the 4 th mo), two patients were lost to follow up and two patients dropped out (1 for orticaria, 1 for gastric burning). Of the remaining 18 patients, levels of serum iron started to rapidly increase within the 2 nd mo of treatment, P < 0.05), whereas serum ferritin and hemoglobin needed a longer period to significantly improve their serum levels (mo 4) P < 0.05. The product was safe, easy to administer and well tolerated by patients. CONCLUSION:These data suggest a potential new treatment for IBD patients with iron deficiency chronic anemia and warrant further larger controlled studies.

show abstract

Section: Discussionmentioning

confidence: 99%

A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study

Belluzzi

Roda²,

Tonon³

et al. 2007

WJG

View full text Add to dashboard Cite

show abstract

“…The results of a randomized, controlled, open-label, multicenter study suggested that IV iron sucrose (IS) had a better GI safety profile in comparison to oral iron sulfate, and 5 patients (20.8%) in the oral group and 1 patient (4.5%) in the IV group discontinued the drug due to adverse GI ADEs. Furthermore, only IV iron led to an increase in serum ferritin concentrations (27). In another randomized controlled study, ferric carboxymaltose (FCM) IV and oral iron sulfate were compared.…”

Section: Treatment Of Anemia Due To Ibd and Gi Hemorrhagementioning

confidence: 99%

Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report

Akpınar

Çetiner²,

Keshav³

et al. 2017

Turk J Gastroenterol

View full text Add to dashboard Cite

Iron deficiency (ID) and iron deficiency anemia (IDA) are important signs of gastrointestinal (GI) hemorrhage. Therefore, the evaluation of the GI tract should be a part of the diagnostic protocol in patients with IDA. GI hemorrhage is not a disease but a symptom, which might have different underlying causes. ID and IDA have significant negative impacts on the life quality and work ability, and they may lead to frequent hospitalization, delay of discharge, and increased healthcare costs. Therefore, an optimal management of the disease causing GI hemorrhage should include iron replacement therapy, along with the treatment of the underlying condition. IDA in inflammatory bowel disease (IBD) has received particular attention owing to its high prevalence, probably due to a number of other factors such as chronic hemorrhage, reduced dietary iron intake, and impaired absorption of iron. Historically, in IBD and in patients with GI hemorrhage, the diagnosis and management of IDA have been suboptimal. Options for iron replacement include oral and intravenous (IV) iron supplementation. Oral iron supplementation frequently results in GI side effects, and theoretically, it may exacerbate IBD activity; therefore, IV iron supplementation is usually considered in patients not responding to or not complying with oral iron supplementation or patients having low hemoglobin concentration and requiring prompt iron repletion. The aim of this report was to review the diagnostic and therapeutic considerations of IDA in IBD and GI hemorrhage with a multidisciplinary group of experts and to formulate necessary practical recommendations.

show abstract

“…In IBD patients, high levels of serum transferrin, soluble transferring receptor, and serum EPO predict the response to intravenous iron supplementation, while low levels indicate the need for concomitant EPO therapy [9] . Two comparative trials (oral vs intravenous iron) have recently been published [29,30] , indicating better tolerability of iv iron sucrose therapy.…”

Section: Intravenous Iron Preparationsmentioning

confidence: 99%

Stimulating erythropoiesis in inflammatory bowel disease associated anemia

Tsiolakidou¹,

Koutroubakis

2007

WJG

View full text Add to dashboard Cite

Intravenous Iron Sucrose versus Oral Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease-A Randomized, Controlled, Open-Label, Multicenter Study

Cited by 202 publications

References 26 publications

A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study

A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: A pilot study

Diagnosis and treatment of iron deficiency anemia in patients with inflammatory bowel disease and gastrointestinal bleeding: iron deficiency anemia working group consensus report

Stimulating erythropoiesis in inflammatory bowel disease associated anemia

Contact Info

Product

Resources

About